----item----
version: 1
id: {7B7473C3-3B24-4072-B09E-0E3752B5868F}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/27/PharmAsia News business bulletin
parent: {32110CE4-9FEB-4D8C-9DFF-1F8EA6DC908B}
name: PharmAsia News business bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 71e50873-948b-4ab2-9523-05f964a9bcff

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News business bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News business bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 5749

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>'s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/30/lower-china-growth-for-takeda-but-impact-limited" target="_new">Lower China Growth For Takeda, But Impact Limited</a></p><p>In line with some of its larger multinational peers, Takeda saw weaker growth in China over the past three months, although its relatively small exposure to emerging markets and increases for new products in major markets mean investors do not appear concerned.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/30/lilly-hit-by-china-2q-slowdown" target="_new">Lilly Hit By China 2Q Contraction</a></p><p>Not all pharma multinationals have provided details of their emerging markets performance in the second quarter, but for those that have, it is clear that growth in China has slowed dramatically over the past few months. Lilly was among those to concede to current challenges in this major emerging market, although it remains bullish on long term prospects.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/30/novartis-china-growth-slows-sharply-in-2q" target="_new">Novartis China Growth Slows Sharply In 2Q</a></p><p>China's economic slowdown has hit Novartis hard, with the Swiss multinational's second quarter growth in the country being slashed by around half. Despite the company emphasizing the challenges are short-term, the underlying reasons such as growing generic competition from domestic companies could be far-reaching.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/29/medytox-in-china-jv-deal-aims-to-set-up-more-asian-units" target="_new">Medytox In China JV Deal, Aims To Set Up More Asian Units</a></p><p>After the establishment of its first overseas subsidiary in Taiwan early this year, Medytox has set up a joint venture with China's Bloomage BioTechnology to sell its botulinum toxin products and hyaluronic acid fillers in China. The South Korean biopharma company is aiming to establish more subsidiaries in other major Asian countries as part of plans to directly sell its products in the region.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/28/3sbio-acquires-wansheng-to-bolster-small-molecule-portfolio" target="_new">3SBio Acquires Wansheng To Bolster Small Molecule Portfolio</a></p><p>China's 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/27/biocon-betting-big-on-biosimilars-as-profit-jumps" target="_new">Biocon Betting Big On Biosimilars As Profit Jumps</a></p><p>Biocon, India's biggest biotechnology company, has just reported a 23% year-on-year jump in quarterly net profit, and says it has sharply boosted its research and development spend as it bets heavily on biosimilars.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/23/bukwang-acquires-acer-stake-in-pattern-of-venture-investments" target="_new">Bukwang Acquires Acer Stake In Pattern Of Venture Investments</a></p><p>Bukwang Pharm has purchased a minority stake in US bioventure Acer Therapeutics, which is seeking to list its shares on Nasdaq early next year. The investment is the sixth the South Korean firm has made together with TVM Life Science Capital to gain investment returns and beef up R&D.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/21/korean-pharma-asks-for-govt-support-as-mers-hits-sales" target="_new">Korean Pharma Asks For Govt Support as MERS Hits Sales</a></p><p>South Korean pharma firms have decided to ask the government to support the industry, which is suffering from sales decline due to the recent outbreak of the Middle East Respiratory Syndrome (MERS) coronavirus. They will ask the government to postpone a planned drug price cut by one year in an effort to overcome the MERS impact and proceed with drug development and globalization programs.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/20/pharmaresearch-ipo-draws-robust-interest-amid-biotech-boom" target="_new">PharmaResearch IPO Draws Robust Interest Amid Biotech Boom</a></p><p>Following a series of successful IPOs by South Korean biopharma firms earlier this year, helped by the ongoing biotech rallies at home and in the US, PharmaResearch Products, which focuses on cell and tissue regeneration technology, has priced its shares sharply above the pricing band for its offering.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/27/astrazeneca-tests-biosimilar-waters-through-bevacizumab-jv" target="_new">AstraZeneca Tests Biosimilar Waters Through Bevacizumab JV</a></p><p>AstraZeneca and Japan's Fujifilm Kyowa Kirin Biologics have signed an agreement to set up a UK-based joint venture to develop globally a biosimilar version of bevacizumab, marking the first tentative step into the biosimilars sector by the research-based pharma giant.</p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 243

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>'s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News business bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150727T110000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150727T110000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150727T110000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029393
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News business bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359630
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042430Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

71e50873-948b-4ab2-9523-05f964a9bcff
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042430Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
